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OBJECTIVES We examined to what extent the variation in risk factors for coronary heart disease (CHD)
and the Framingham risk score (FRS) explain the variation in vascular reactivity in adults
aged 30 to 53 years.
BACKGROUND The role of risk factors in determining vascular reactivity in the general population has not
been quantified.
METHODS Risk factors for CHD were measured, and the FRS was calculated in 69 healthy volunteers.
Lipoprotein particle size was measured using proton-nuclear magnetic resonance spectros-
copy. Forearm plethysmography was used to assess blood flow responses to acetylcholine
(ACh), bradykinin (BK), glyceryl trinitrate (GTN), noradrenaline and NG-monomethyl-L-
arginine (L-NMMA).
RESULTS Lower ACh and BK responses were associated with a higher body mass index (BMI), a
higher total cholesterol to high-density lipoprotein (HDL) cholesterol ratio, lower HDL
cholesterol and a cigarette smoking habit (all p  0.05). Higher low-density lipoprotein
(LDL) cholesterol was also associated with a lower BK response (p  0.001). A decreased
GTN response was associated with a higher BMI and total cholesterol to HDL cholesterol
ratio (both p  0.05). A decreased L-NMMA response was associated with a smoking habit
(p  0.001). Lipoprotein particle sizes did not independently predict any vascular response.
A high FRS was associated with a reduced response to ACh (p  0.07), BK (p  0.003) and
L-NMMA (p 0.003), and the relationship was stronger in women than in men. Altogether,
risk factors explained 13%, 9%, 8% and 15% of the response to ACh, BK, GTN and
L-NMMA, respectively.
CONCLUSIONS Lipids, BMI and smoking are important determinants of vascular reactivity. The FRS is
predictive of agonist-stimulated, endothelium-dependent vasodilation and basal NO release.
However, much of the variation in the vascular responses to these drugs, at this age, remains
unexplained. (J Am Coll Cardiol 2001;38:1814–20) © 2001 by the American College of
Cardiology
Vascular dysfunction has been implicated as an early event
in atherogenesis (1). A particularly important aspect of
vascular function is the integrity of the L-arginine–nitric
oxide (NO)–cyclic guanosine monophosphate pathway.
Endothelium-derived NO is an antiatherogenic molecule
that has effects on vascular tone, homeostasis and platelet
function (2). Previous studies in humans have suggested that
risk factors for coronary heart disease (CHD), such as
obesity (3), dyslipidemia (4–7), hypertension (8), cigarette
smoking (9) and lack of physical activity (10), are associated
with defects in NO-mediated vascular function. In many of
these risk-factor studies, subjects with extremely abnormal
risk-factor levels were compared with healthy control sub-
jects. Recent studies have also reported a very high correla-
tion between lipoprotein particle size and aspects of vascular
function (11,12). However, many risk factors are continuous
variables and are not merely present or absent, but present to
a greater or lesser extent in every individual.
The purpose of this study was to quantify to what extent
the variation in these risk factors, across the range usually
found in the general population and not just at the extremes
of the range, predict interindividual variations in vascular
function. We also examined whether the Framingham risk
score (FRS), calculated for each subject, predicts NO release
or response.
METHODS
Subjects. The study was approved by the local Ethics
Committee, and all participants gave written, informed
consent to participate. The participants were recruited from
a cohort of 201 healthy subjects who had taken part in a
separate study within the preceding 12 months (13). All
subjects who had a history of cardiovascular disease were
recruited from two general practices in London. Subjects
with diabetes mellitus were excluded on the basis of a
clinical history and a random blood glucose test taken at
the time of the study (all 7 mmol/l) (Table 1). In the
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United Kingdom, general practice registries provide a good
sampling frame for the general population. Among this
cohort of 201 subjects, 69 took part (34%). All were
between 30 and 53 years old, and 50% were women. All
participants gave their informed consent. Risk-factor mea-
surements were performed one year before the vascular
study. Blood pressure was also measured at the time of the
vascular study, and these data are used in this analysis.
Assessment of risk factors. A standardized questionnaire
was used. The average weekly consumption of alcohol units
was calculated, and cigarette smoking exposure was quanti-
fied as pack-years. Obesity was defined as a body mass index
(BMI) 30 kg/m2. A score combining the duration and
intensity of physical activity was calculated and dichoto-
mized as low (weekly score 10) or high. Before the
vascular study, blood pressure in the right arm was measured
three times, using an automated digital monitor (Omron
705CP, OMRON, Tokyo, Japan), with the subject seated
after a 5-min rest. The mean value of the three measure-
ments is presented. For each subject, the FRS was calculated
by using the most recent FRS equation (14).
In vivo vascular function study. Subjects were asked to
refrain from drinking alcohol and caffeine-containing bev-
erages 24 h before the study. Studies were performed in a
quiet, temperature-controlled (24–27°C) laboratory. Fore-
arm blood flow was measured by venous occlusion plethys-
mography, as described in detail elsewhere (15). Forearm
blood flow was measured in response to intrabrachial
infusion of acetylcholine (ACh) (Sigma, St. Louis, Mis-
souri; doses of 25, 50 and 100 nmol/l, each dose for 3 min);
bradykinin (BK) (Clinalfa, Laufelfingen, Switzerland; doses
of 10, 30 and 100 pmol/min, each dose for 3 min); glyceryl
trinitrate (GTN) (David Bull Laboratories, Warwick, U.K.;
doses of 4, 8 and 16 nmol/min, each dose for 5 min);
noradrenaline (Levophed; Sanofi Winthrop Ltd.,
Guildford, U.K.; doses of 60, 120 and 240 pmol/min, each
dose for 5 min) and NG-monomethyl-L-arginine (L-
NMMA) (Clinalfa, Laufelfingen, Switzerland; doses of 1, 2
and 4 mol/min, each dose for 5 min). Each drug infusion
was separated by a 10-min saline washout period. The order
of vasodilator infusions (ACh, BK and GTN) was random-
ized. L-NMMA was always infused last, because of its long
duration of action. Flow was recorded for 10 s every 15 s,
and the mean value of the last four measurements of each
recording period was used for data analysis. Blood flow was
expressed as milliliter of blood per 100 ml of forearm
volume per minute (ml/100 ml per min). At the end of each
study, the length and volume of the infused arm were
measured.
Laboratory methods. Total cholesterol, high-density li-
poprotein (HDL) cholesterol and triglycerides were mea-
sured using enzymatic colorimetric methods. High-density
lipoprotein cholesterol was measured directly after stabili-
zation of other lipoproteins. Low-density lipoprotein
(LDL) cholesterol was calculated using the Friedewald
formula. Venous blood samples were also taken before and
immediately after vascular studies for plasma glucose anal-
ysis. Proton-nuclear magnetic resonance (PNMR) spectros-
copy was used to quantify LDL, HDL and very-low-density
lipoprotein (VLDL) cholesterol subclasses and the average
particle size, as described previously (16). A repeatability
study on blinded duplicate samples showed good repeatabil-
ity; 0.91 for VLDL particle size, 0.92 for LDL particle size
and 0.96 for HDL particle size.
Heart rate variability. A 5-min electrocardiographic
(ECG) recording was obtained using a lead ensuring a
prominent R wave, after 5 to 10 min in the supine position.
The ECG signal was digitized at 1,000 Hz, using a
computer with an analog-to-digital card (AT-MIO-16E2,
National Instruments, Austin, Texas). Autoregressive
power spectral analysis was used to determine the spectral
power in the following frequency bands: high-frequency
power (0.15 to 0.45 Hz), low-frequency power (0.04 to
0.15 Hz) and very-low-frequency power (0.01 to 0.04 Hz),
and the total power was the sum of these.
Statistical analysis. The response to drugs was defined as
the ratio of flow during drug infusion to flow during
baseline saline infusion. We used repeated measures analysis
of covariance to define how the response to drugs, across the
three doses, varied by risk-factor level, adjusting for age,
Abbreviations and Acronyms
ACh  acetylcholine
BK  bradykinin
BMI  body mass index
CHD  coronary heart disease
FRS  Framingham risk score
GTN  glyceryl trinitrate
HDL  high-density lipoprotein
LDL  low-density lipoprotein
L-NMMA  NG-monomethyl-L-arginine
NO  nitric oxide
PNMR  proton-nuclear magnetic resonance
Table 1. Characteristics of Subjects
Men
(n  34)
Women
(n  35)
Age (yr) 37.8  3.9 37.9  3.5
BMI (kg/m2) 25.0  3.4 25.6  5.6
Smokers (pack-years) 8.2  11.0 6.3  11.0
Systolic blood pressure (mm Hg) 128.9  11.6 119.4  11.9
Diastolic blood pressure (mm Hg) 82.0  9.8 75.2  9.5
Total cholesterol (mmol/liter) 5.7  1.2 5.3  1.2
LDL cholesterol (mmol/liter) 3.3  1.1 3.0  0.8
HDL cholesterol (mmol/liter) 1.57  0.4 1.82  0.4
HDL cholesterol to total
cholesterol ratio
0.28  0.09 0.33  0.13
Triglycerides (mmol/liter) 1.72  1.5 1.25  1.9
Plasma glucose (mmol/l) 5.4  0.6 5.0  0.5
Total spectral power (Hz) 1,204 (1,344) 1,106 (1,369)
Data are presented as the mean value  SD or median value (distance between 25th
and 75th centiles).
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density
lipoprotein.
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gender, basal flow and flow in the control arm. Because the
flow data had a skewed distribution, they were log-
transformed for these analyses. The contribution of each
risk factor to the variation in drug response between
individuals was quantified by noting the change in the
intersubject variance (i.e., the change in the between-subject
R2) when that risk factor was added to the model that
already included age, gender, basal flow and flow in the
control arm. For ACh and BK, independence from the
GTN response was checked by including the GTN response
in the models. The models were then repeated by simulta-
neously including BMI, lipids, systolic and diastolic blood
pressure and smoking to examine which factors were inde-
pendently associated with the response, as well as the
combined contribution of the risk factors to the intersubject
variation in response. The relationship of lipoprotein parti-
cle size and heart rate variability to vascular response was
examined in separate models.
RESULTS
Subject characteristics. The background characteristics of
the participants are shown in Table 1. Five subjects were
non-white. Fourteen subjects (20%) had hypertension, de-
fined as antihypertensive drug use or systolic blood pressure
140 mm Hg or diastolic blood pressure 90 mm Hg. Six
subjects were taking the oral contraceptive pill, and one was
receiving hormone replacement therapy. Three women were
postmenopausal. The pattern of risk-factor associations
shown subsequently was the same when non-white subjects,
postmenopausal women or women using hormone replace-
ment therapy or hormonal contraception were excluded.
The majority of women (77%) were in the follicular phase of
their menstrual cycle when studied, and the associations
noted subsequently were not affected by adjusting for the
cycle phase. No participants had a history or symptoms of
CHD. There was considerable variation in the response to
drugs between subjects. For example, with the highest drug
dose, blood flow increased from 1.7- to 4.9-fold for GTN,
1.7- to 9.7-fold for ACh, 1.5- to 6.7-fold for BK and 0.52-
to 1.1-fold for L-NMMA.
Associations between vascular response and basal flow,
flow in the control arm, age and gender. The differences
in basal flow between subjects contributed significantly to
the variance in the ratio of flow during drug infusion to flow
at baseline, accounting for 16%, 23%, 20% and 15% of the
variation in the responses to ACh, BK, GTN and
L-NMMA, respectively. Changes in systemic flow during
the vascular study, as measured by changes in flow in the
control arm, accounted for further variation in the responses
to ACh, BK, GTN and L-NMMA between subjects (14%,
17%, 9% and 30%, respectively). Accordingly, all models
examining the role of risk factors were first adjusted for basal
flow and flow in the control arm. The age range of subjects
was narrow, and, accordingly, age did not account for any of
the variation in response. Gender was also unrelated to the
vascular response independently of basal flow and control
arm flow.
Association between classic CHD risk factors and vas-
cular responses. Table 2 shows the association between
established CHD risk factors and drug responses adjusted
for age, gender, basal flow and flow in the control arm. In
addition to the risk factors shown, alcohol intake and
physical activity were also examined, and they showed no
association with any of the drug responses and were not
included in any of the combined models.
Agonist-stimulated, endothelium-dependent vasodila-
tion. A similar pattern of risk-factor associations was found
for BK and ACh responses (Table 2), with the responses
being lower in those with a higher BMI, total cholesterol to
HDL cholesterol ratio, lower HDL cholesterol and in those
who smoked cigarettes. Low-density lipoprotein cholesterol
was associated with a BK response only. The associations
were independent of the response to GTN. Table 2 shows
how much of a difference in drug response was associated
with a given difference in the risk factors for both genders
combined. For example, for every 1 kg/m2 higher BMI,
there was a 3% lower response to ACh and BK. The
association between BMI and drug response was indepen-
dent of forearm volume for BK (p  0.04), but not ACh.
Overall, BMI, total cholesterol to HDL cholesterol ratio,
Table 2. Percent Change in Each Drug Response for Per Unit Change in Risk Factor (With 95% Confidence Interval)
ACh BK GTN NA L-NMMA
SBP (10 mm Hg) 0.8% (8, 10) 0.4% (1, 0.1) 2% (7, 4) 3% (9, 3) 0% (3, 3)
DBP (10 mm Hg) 3% (7, 15) 0.1% (1, 0.6) 2% (8, 5) 4% (11, 3) 0.4% (3, 4)
BMI (kg/m2) 3%* (5, 0) 3%† (4, 1) 2%* (6, 1) 1% (1, 3) 1% (2, 0)
LDL cholesterol (mmol/l) 3% (12, 7) 9%† (14, 4) 4% (10, 2) 6% (2, 14) 2% (5, 1)
HDL cholesterol (mmol/l) 36%* (7, 73) 30%† (11, 51) 11% (4, 30) 13% (18, 4) 0.2% (8, 9)
Total cholesterol to HDL
cholesterol ratio
9%* (16, 2) 9%‡ (13, 5) 5%* (10, 1) 4% (9, 1) 2% (0.5, 5)
Triglycerides (mmol/l) 3% (9, 2) 3% (7, 0) 3% (6, 0.3) 1% (3, 6) 1% (3, 0)
Total spectral power 4% (8, 18) 4% (4, 1) 9%* (1, 17) 5% (3, 14) 3% (1, 7)
Smoking§ 23%* (40, 2) 17%* (29, 3) 1% (16, 15) 8% (22, 9) 13%† (22, 5)
*p  0.05, †p  0.005, ‡p  0.0005, adjusted for basal flow, flow in control arm, age and gender. §At least 10 pack-years versus no pack-years.
ACh acetylcholine; BK bradykinin; DBP diastolic blood pressure; GTN glyceryl trinitrate; L-NMMA NG-monomethyl-L-arginine; NA noradrenaline; SBP
systolic blood pressure; other abbreviations as in Table 1.
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HDL and LDL cholesterol and smoking accounted for 5%,
7%, 7%, 4% and 7% of the variation in the ACh response,
respectively, and 9%, 11%, 9%, 10% and 4% of the variation
in the BK response, when each factor was examined
separately in the model adjusted for age, gender, basal flow
and control arm flow. Because these risk factors cluster with
each other, the total variance explained by the entire
risk-factor profile is less than the sum of the variance
explained by each risk factor examined separately. When
entered into the model simultaneously, they accounted for
13% of the ACh response and 19% of the BK response. The
only risk factor significantly associated with a drug response,
independently of other factors in these models, was smok-
ing, which remained independently associated with the
ACh response (p  0.04).
When each gender was examined separately, the associ-
ations of drug response with total cholesterol to HDL
cholesterol ratio and HDL cholesterol were less strong in
men than in women, although not significantly so (data not
shown), and in men, there was no evidence of an association
between BMI and BK response. In contrast, LDL choles-
terol was associated with a BK response more strongly in
men than in women (data not shown).
Endothelium-independent vasodilation. Endothelium-
independent vasodilation, as assessed by the GTN response,
was associated with BMI and total cholesterol to HDL
cholesterol ratio (Table 2). The total cholesterol to HDL
cholesterol ratio explained 6% of the variation in the
GTN response and BMI accounted for 5%. When all of the
risk factors were entered into the model simultaneously,
they accounted for 8% of the variance in response, and no
risk factor was statistically significant on its own.
When both genders were examined separately, the asso-
ciation between total cholesterol to HDL cholesterol ratio
and GTN response was of a similar magnitude in both
genders, but the relationship between BMI and GTN
response was only significant in women. Among women, for
every for every 1 kg/m2 increase in BMI, there was a 3%
reduction in the GTN response (p  0.006), and this was
independent of forearm volume (p  0.005 after adjust-
ment).
Basal NO release. The only risk factor that showed a
significant association with basal NO release, as assessed by
L-NMMA response, was smoking. Subjects who had at
least 10 pack-years of smoking had a 13% lower L-NMMA
response, as compared with nonsmokers (Table 2). Overall,
smoking accounted for 9% of the interindividual variation
in response to L-NMMA. The relationship was apparent in
both genders. The relationship was not attributable to a
generalized increased vasoconstrictor response in smokers,
because there was no difference in the noradrenaline re-
sponse with smoking (Table 2).
With all risk factors entered into the model simulta-
neously, they accounted for 15% of the interindividual
variation in the L-NMMA response, and the smoking
association remained significant (p  0.001).
Nonclassic CHD risk factors. A higher PNMR
spectroscopy-defined HDL particle size was associated with
a higher response to BK (18% higher for every nanometer
increase in average HDL diameter, p  0.02 adjusted for
basal flow, flow in the control arm, age and gender). The
HDL particle size was highly correlated with both HDL
cholesterol and total to HDL cholesterol ratio (r  0.8 and
r  0.7, respectively) and was not associated with the BK
response independently of either of these. No other associ-
ations were found between average LDL or VLDL particle
size and any of the drug responses. In particular, having a
pattern B type LDL (average particle size 20.5 nm) was
not associated with an altered drug response.
Total spectral power was associated with an ACh re-
sponse, with those in the bottom quartile of spectral power
having a 24% lower response than the remaining subjects
(p  0.03 adjusted for basal flow, flow in the control arm,
age and gender). Total spectral power also showed an
association with GTN response, with those in the bottom
quartile having a 20% lower response than those in the top
quartile (p  0.048). Spectral power accounted for 6% and
5% of the interindividual variation in ACh and GTN
responses, respectively. The difference in both ACh and
GTN responses with spectral power was independent of
BMI and smoking, but was reduced to 18% (p  0.1) for
ACh and 15% (p  0.1) for adjustment of lipids.
Framingham risk score. The relationship between FRS
and vascular response is shown in Table 3. A higher FRS
was associated with a reduced response to BK and
L-NMMA. These relationships were stronger for women
than for men and were nonsignificant in men when exam-
ined separately (data not shown). A higher FRS was also
associated with a reduced response to ACh in women.
There was no relationship between FRS and response to
GTN. As shown in Table 4, the percentage of the variance
Table 3. Difference in Drug Response Per Quartile Increase in Framingham Risk Score (2000)
(95% Confidence Interval) in Men and Women
ACh BK GTN L-NMMA
10%, p  0.07 11%, p  0.003 0.01%, p  0.9 6%, p  0.003
(2%, 1%) (17%, 4%) (7%, 7%) (10%, 2%)
Abbreviations as in Table 2.
Table 4. Percent Variance in Drug Response Explained by
Framingham Risk Score Beyond That Explained by Age and
Gender
ACh BK GTN L-NMMA
4% 7% 0% 7%
Abbreviations as in Table 2.
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in drug response explained by the score was much less than
that in models in which these risk factors were entered
simultaneously, as described earlier. When both the score
and risk factors were entered into the models simulta-
neously, the risk factors explained a further 8% to 10% of
the variance in the response to the drugs.
DISCUSSION
Studies that compare vascular function between extremes
of a distribution (e.g., obese or hypercholesterolemic pa-
tients and control subjects) provide useful information on
the pathophysiologic mechanisms that may be involved in
vascular dysfunction, with relatively small sample sizes.
However, such studies do not give insight into the likely
quantitative effect of risk factors in the general population.
In contrast, our study, in a sample representative of the
range of factors and vascular function found in the general
population, provides a different type of information that
allows quantification of the role of a given risk factor in
the variation in vascular responses in the population. The
results show that BMI and lipids are important determi-
nants of stimulated NO release and responsiveness to an
NO donor in forearm resistance vessels in the general
population. It is clear that HDL cholesterol and the total
cholesterol to HDL cholesterol ratio are as important as
LDL cholesterol, a finding that is in keeping with the
relative importance of these measures as risks factors for
cardiovascular events. In the presence of a defective response
to an NO donor (GTN), it is not possible to state with
certainty whether a reduced response to ACh and BK
primarily reflects defective NO release or diminished re-
sponsiveness to NO. However, the association of BMI,
lipids and smoking with ACh and BK responses was
statistically independent of the GTN response, suggesting
an effect on stimulated NO release. Cigarette smoking is an
important determinant of both stimulated and basal NO
release. However, our study also shows that, although these
factors are clearly important, they explain relatively little of
the variation in the measure of vascular function we have
used (13% for ACh, 19% for BK, 8% for GTN and 15% for
L-NMMA). Approximately 30% to 45% of the variation in
the change in flow in response to drugs between subjects
was accounted for by differences in resting basal flow and
the concomitant changes in flow in the control arm (data
not shown). The rest of the variation must either be due to
measurement error in this type of study or as-yet unidenti-
fied major determinants of variation in vascular function,
that are worth identifying. Previous studies of vascular
responsiveness that have focused on more than one risk
factor have mostly examined flow-mediated dilation in the
brachial artery (17,18) or coronary vessels (19,20), rather
than the forearm resistance vessels.
Body mass index and vascular function. Our data are
consistent with previous studies showing that higher BMI is
associated with reduced endothelium-dependent (BK and
ACh responses) vasodilation (3,21). Unlike the previous
studies, however, we have also demonstrated that obesity is
associated with a reduced response to NO donors (GTN
response), at least in women. The mechanisms may be
related to the inflammatory effect of obesity (22) or associ-
ated oxidative stress (21), but further studies are required to
test this directly.
High-density lipoproteins and vascular responses. High
HDL cholesterol and a low total cholesterol to HDL
cholesterol ratio were associated with a greater response to
ACh, BK and GTN in forearm resistance vessels. This is
consistent with a recent study in which Li et al. (23) studied
the relationship between lipoproteins and conduit vessel
response in 63 subjects with CHD and 45 control subjects.
They found that only elevated HDL cholesterol was signif-
icantly related to flow-mediated vasodilation of the brachial
arteries. It has become clear that HDL cholesterol is a major
determinant of cardiovascular risk, and it is interesting to
note that it is a prime determinant of vascular reactivity in
a general, asymptomatic population.
Low-density lipoprotein cholesterol and its subfractions
and vascular responses. High LDL cholesterol levels were
associated with an impaired BK response, but responses to
other agents were unaffected. This is in contrast to studies in
which individuals with high or normal total or LDL
cholesterol were compared; these showed that increased
total or LDL cholesterol is associated with impaired ACh-
stimulated, endothelium-dependent vasodilation in forearm
resistance vessels (24–26) and coronary arteries (19). It
remains to be determined whether the differences in those
studies are due to the selection of subjects with high
cholesterol, who also have other risk factors (e.g., low HDL
cholesterol), which affects the vascular response, or whether
the relatively narrow range of LDL cholesterol levels in the
present study precluded detection of a weak effect of LDL
cholesterol. In a small study (n  24), Gilligan et al. (25)
found no difference in the bradykinin response between
hypercholesterolemic and normal subjects, but the study was
underpowered (27). We did not replicate previous findings
of an association between impaired coronary vasoconstrictor
response to L-NMMA in coronary vessels and hypercholes-
terolemia, and this may partly reflect differences in the
vascular bed studied (20).
The relationship between LDL particle size (measured by
gradient gel electrophoresis) and endothelial function was
examined recently by Vakkilainen et al. (28). They demon-
strated that men with small LDL particles (as measured by
gradient gel electrophoresis) have a 39% lower forearm
vascular response to ACh (but not sodium nitroprusside, an
NO donor), as compared with men with large LDL
particles. Our study does not support their findings, even
when the top and bottom quartile groups for LDL particle
size or when male gender alone (n  34) were compared.
The reason for this difference is unclear, but may be related
to differences in the study population (younger mean age in
our study) or LDL particle measurement methods (gradient
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gel electrophoresis versus PNMR), or both. Clearly, further
studies are required to address this issue definitively, and the
findings of Vakkilainen’s study and ours may form the basis
for a power calculation for future studies.
Smoking. We found an inverse association between ACh-
and BK-stimulated, endothelium-dependent vasodilation
with cigarette smoking. In addition, we found that smokers
have a lower response to L-NMMA than do nonsmokers.
This suggests that either basal NO production is diminished
in smoking or there is diminished NO bioavailability, or a
combination of these two factors. It has been shown that
smoking is associated with depletion of cofactors for NO
synthase, such as tetrahydrobiopterin (29) and increased
oxidative stress (30). Our finding that there was no signif-
icant association between smoking and the noradrenaline
response indicates that the defective L-NMMA response in
smoking is unlikely to be due to a generalized defect in
vasoconstrictor responses. Previous studies of forearm resis-
tance vessel responsiveness in smokers and nonsmokers have
not found any defect in stimulated NO production, but they
had smaller sample sizes (31–33). The result of a large
recent study was consistent with our findings (34). In
general, studies are consistent in their finding that smoking
decreases basal NO release (33–35).
Blood pressure. With respect to blood pressure, defective
endothelium-dependent vasodilation has been demon-
strated in subjects with established essential hypertension
(8,36), although this association has been challenged (37).
In our study, systolic and diastolic blood pressure (measured
at the beginning of each study) and pulse pressure were not
associated with changes in any drug responses (data not
shown), nor was there any association with blood pressure
measured one year before the study. This may be due to the
low blood pressure range (systolic: 96 to 155 mm Hg) seen
in our cohort of participants, as well as the fact that
relatively few (14/69) participants had hypertension (de-
fined as systolic blood pressure 140 mm Hg or diastolic
blood pressure 90 mm Hg or antihypertensive drug use).
Alternatively, it is possible that previous associations be-
tween hypertension and the vascular response may reflect
associated risk factors (e.g., insulin resistance) that were not
prevalent in our study group, rather than a direct effect of
blood pressure itself or a direct effect of the endothelium on
blood pressure.
Heart rate variability and vascular response. We found
that lower total reduced heart rate variability was associated
with a reduced response to GTN, although not indepen-
dently of lipids. In the general population, heart rate
variability is associated with an increased incidence of CHD
and postinfarction mortality (38). The significance of our
finding is not clear, but it suggests the role of the autonomic
nervous system in altering the vascular response to NO and
is worthy of further investigation.
Framingham risk score and vascular responses. Interest-
ingly, the most widely used cardiovascular risk prediction
tool—the FRS—is clearly predictive of the responses to
ACh, BK and NO, but not to GTN. This suggests that,
overall, conventional risk factors are more important for
agonist-stimulated, endothelial-dependent vasodilation and
basal NO-mediated dilation than for NO responsiveness.
This is consistent with flow-mediated vasodilation studies
wherein the total number of risk factors was associated with
the response during reactive hyperemia, but not the re-
sponse to GTN (18). The association was clearer in women
than in men. This may be because the FRS is more accurate
in predicting CHD risk in women than in men. Alterna-
tively, it is possible that NO release is more important to
CHD risk in women than in men. Whatever the explana-
tion, it is important that forearm responses are significantly
influenced by the score, and this strengthens the use of
forearm responses as a surrogate marker in clinical studies of
new therapies.
Methodologic considerations. One issue to consider in
this study is that, apart from blood pressure, risk factors
were measured one year before the vascular study. Contem-
poraneous measures of these factors might have shown
stronger associations with the vascular response. However,
most of the risk factors we measured (e.g., HDL and LDL
cholesterol and BMI) have high tracking (i.e., the rank
order of these values in a group of people will change very
little over the course of a year), and we confirmed that
smoking status had not changed. Thus, differences in the
timing of risk-factor measurement should have little bearing
on the pattern of associations seen, unless it is the instan-
taneous value of these factors, rather than their long-term
impact on the vascular response, that matters most. Most of
the hypotheses on how these risk factors might affect
vascular responsiveness assume that they predict vascular
function in the longer term, rather than just instantaneously.
As such, our study has the advantages of a cohort study in
that what we are measuring is the predictive value of these
factors over one-year follow-up.
Conclusions. Lipids and smoking, but not blood pressure
or lipoprotein particle size, were associated with demonstra-
ble variations in the NO pathway in early middle age. Many
of the changes occur in response to NO, rather than just as
endothelium-dependent responses, although for smoking it
appears as though there is a true defect in basal NO
generation. A high FRS is predictive of reduced agonist-
stimulated and basal endothelium-dependent vasodilation.
The vast majority of the interindividual variation in vascular
function in the general population cannot be explained by
classic cardiovascular risk factors.
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